ACHV Logo

Achieve Life Sciences, Inc. (ACHV) 

NASDAQ
Market Cap
$176.17M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
246 of 776
Rank in Industry
141 of 433

Largest Insider Buys in Sector

ACHV Stock Price History Chart

ACHV Stock Performance

About Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Insider Activity of Achieve Life Sciences, Inc.

Over the last 12 months, insiders at Achieve Life Sciences, Inc. have bought $91,700 and sold $0 worth of Achieve Life Sciences, Inc. stock.

On average, over the past 5 years, insiders at Achieve Life Sciences, Inc. have bought $53,733 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Bencich John (CEO) — $45,850. Stewart Richard Alistair (Executive Chairman) — $45,850.

The last purchase of 10,000 shares for transaction amount of $45,850 was made by Bencich John (CEO) on 2024‑03‑04.

List of Insider Buy and Sell Transactions, Achieve Life Sciences, Inc.

2024-03-04PurchaseCEO
10,000
0.0492%
$4.58$45,850+4.04%
2024-03-04PurchaseExecutive Chairman
10,000
0.0492%
$4.58$45,850+4.04%
2023-05-30PurchaseCEO
5,000
0.0246%
$5.50$27,500-26.44%
2022-11-18PurchaseCEO
22,000
$0$0+107.53%
2021-05-27PurchaseCEO
6,000
0.0716%
$7.00$42,000-3.40%
2019-06-11Sale10 percent owner
312,145
4.6633%
$3.11$972,288-71.03%
2019-06-11Purchase10 percent owner
12,813
0.2335%
$3.80$48,689-71.03%
2019-05-23PurchaseChairman & CEO
17,500
0.2417%
$3.61$63,093-74.93%
2016-08-19SaleCFO
2,760
0.0092%
$0.57$1,573-21.05%
2016-06-13SalePresident and CEO
9,712
0.032%
$1.03$9,959-50.96%
2016-06-13SaleEVP, CMO
2,874
0.0095%
$1.03$2,947-50.96%
2016-03-15SalePresident and CEO
24,066
0.0807%
$0.83$19,975-30.12%
2016-03-15SaleEVP, CMO
6,508
0.0218%
$0.83$5,402-30.12%
2016-03-15SaleCFO
1,668
0.0056%
$0.83$1,384-30.12%
2015-08-18SaleCFO
2,854
0.0103%
$2.76$7,877-62.45%
2015-06-12SalePresident and CEO
9,142
0.0381%
$2.69$24,592-56.36%
2015-06-12SaleEVP, CMO
2,816
0.0117%
$2.69$7,575-56.36%
2015-05-20SalePresident and CEO
15,086
0.0639%
$1.88$28,362+11.11%
2015-05-20SaleEVP, CMO
4,184
0.0177%
$1.88$7,866+11.11%
2014-08-13SalePresident and CEO
36,682
0.1682%
$3.17$116,282-30.49%

Insider Historical Profitability

<0.0001%
Bencich JohnCEO
76724
0.2234%
$5.1343<0.0001%
Stewart Richard AlistairExecutive Chairman
38501
0.1121%
$5.1320<0.0001%
COHEN STEVEN A/SAC CAPITAL MGMT LP10 percent owner
1454752
4.2362%
$5.1310
S A C CAPITAL MANAGEMENT L L C10 percent owner
1454752
4.2362%
$5.1310
SAC CAPITAL ADVISORS LLC10 percent owner
1454752
4.2362%
$5.1310

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Franklin Templeton Investments$17.19M17.375.96MNew+$17.19M0.01
Sofinnova$6.9M4.421.52MNew+$6.9M0.01
The Vanguard Group$4.31M2.76948,441+56.58%+$1.56M<0.0001
Altium Capital Management Lp$3.8M2.43835,470New+$3.8M0.45
Nantahala Capital Management Llc$2.97M1.9654,000New+$2.97M0.14
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.